"A positive result in this study would represent a significant milestone for Endonovo and the field of bioelectronic medicine. We are moving to establish Endonovo as the leader in electroceuticals-based regenerative medicine. Our competitors in the bioelectronic medicine space are primarily developing implantable devices targeting the inflammatory response, and our competitors in regenerative medicine are developing cell therapies, biologics and gene therapies to treat many of these diseases, which are more expensive to develop and present significantly more safety concerns for potential patients.
"Our technology presents a lucrative opportunity to develop a non-invasive platform device that can be used to treat cardiovascular, cerebrovascular and peripheral artery disease as well as ischemia/reperfusion injuries," concluded Mr. Collier.
News 
Market Data 
Discover 
